The Peptide NewsroomPeptide research, industry and supply-chain headlines

Us Weekly Pitches Calocurb as a GLP-1 Alternative, But the Numbers Are the Brand's

Topic card: glp-1

A shopping feature published by Us Weekly promotes Calocurb, a three-ingredient capsule pitched at readers who want appetite suppression without an injectable GLP-1 prescription. The piece carries an affiliate disclosure at the top, which is the first thing worth knowing about the figures further down.

The formula is Amarasate, described as a New Zealand-derived bitter plant extract, plus rosemary leaf extract and vegetable oil. Amarasate is the active piece: Us Weekly says it targets bitter taste receptors in the small intestine, which stimulates GLP-1 and other gut hormones and slows gastric emptying so food stays in the stomach longer.

Bitter receptors, familiar hormone

That mechanism is genuinely interesting, because it is the same hormonal pathway the injectable drugs work on, approached from the opposite end. Rather than supplying a GLP-1 analog, the pitch is that a bitter compound prompts the gut to release more of its own.

It is also the point where a supplement story usually outruns its evidence. Stimulating a hormone and producing a measurable change in body weight are different claims, and only one of them is easy to demonstrate.

Where the numbers come from

Us Weekly reports that the capsules can reduce hunger by 30 percent, cravings by 40 percent and calorie intake by 18 percent, and attributes all three figures to the brand. No study is named, no sample size is given, and no comparison group appears anywhere in the article.

Three percentages without a denominator are marketing copy, not results. The rest of the supporting material is customer reviews quoted from the retailer, which is not evidence of anything beyond what those customers wrote.

What the brand recommends

The article relays a ramp-up schedule from Calocurb: one capsule an hour before a meal for the first two days, building to two capsules twice daily after day five. Mild digestive discomfort in the first few days is described as expected and not persistent.

Bottom line

The honest version of this story is that a plant extract with a plausible gut-hormone mechanism is being sold on numbers its own manufacturer generated. Us Weekly concedes the product is not a miracle pill and still requires diet and exercise, which is the most reliable sentence in the piece.

Source: Us Weekly. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

UK Supplier Lists Retatrutide and GHK-Cu Vials, But First-Lot Certificates Are Still Pending

UK supplier Altapeptides has launched an online catalogue of research peptides including Retatrutide and GHK-Cu, with detailed vial specifications and a promise that no lot ships without a matching certificate of analysis. The first lots are still pending, and none of those certificates has been published yet.

Endogenous GLP-1 Rises Across Alzheimer's Stages, But Study Calls It a Failing Response

A study in General Psychiatry reports that levels of the body's own GLP-1 rose progressively from cognitively normal individuals through mild cognitive impairment to Alzheimer's dementia across two cohorts totaling 250 participants. The authors read the elevation as a compensatory response that fails, and propose it as a biomarker rather than a treatment target.

GLP-1 Drugs Reshape Diabetes Care, But New Paper Finds Little Change in Wider Life Outcomes

A new NBER working paper from University of Chicago economist Robert Kaestner and coauthor Cuiping Schiman found little evidence that GLP-1 use among adults with diabetes changed mental health, employment or marital status. The authors say the result does not question the drugs' documented medical benefits, and that their measures may miss subtler changes.